The present invention relates to hydroxy-triglycerides, their synthesis, a pharmaceutical and/or nutraceutical composition which comprises at least one of said hydroxy-triglycerides, and a method which comprises the administration to a patient of a therapeutically effective quantity of at least one of said hydroxy-triglycerides or at least one of said pharmaceutical and/or nutraceutical compositions, for the prevention and/or treatment of at least one disease selected from cancer, metabolic/cardiovascular diseases, and/or neurological/inflammatory diseases.

The present invention relates to hydroxy-triglycerides, their synthesis, a pharmaceutical and/or nutraceutical composition which comprises at least one of said hydroxy-triglycerides, and a method which comprises the administration to a patient of a therapeutically effective quantity of at least one of said hydroxy-triglycerides or at least one of said pharmaceutical and/or nutraceutical compositions, for the prevention and/or treatment of at least one disease selected from cancer, metabolic/cardiovascular diseases, and/or neurological/inflammatory diseases.

Provided is a method of producing a purified chlorogenic acid-containing composition, including: a first step of dispersing or dissolving a raw material chlorogenic acid-containing composition in an aqueous solution of organic solvent; a second step of removing a precipitate from a dispersion or a solution obtained in the first step; and a third step of bringing a solution obtained in the second step into contact with activated carbon including activated carbon (A) having a pore volume of from 0.3 mL/g to 1.0 mL/g and activated carbon (B) having a pore volume larger than that of the activated carbon (A), in which a difference [(B)−(A)] in pore volume between the activated carbon (A) and the activated carbon (B) is from 0.1 mL/g to 1.5 mL/g.

Provided is a method of producing a purified chlorogenic acid-containing composition, including: a first step of dispersing or dissolving a raw material chlorogenic acid-containing composition in an aqueous solution of organic solvent; a second step of removing a precipitate from a dispersion or a solution obtained in the first step; and a third step of bringing a solution obtained in the second step into contact with activated carbon including activated carbon (A) having a pore volume of from 0.3 mL/g to 1.0 mL/g and activated carbon (B) having a pore volume larger than that of the activated carbon (A), in which a difference [(B)−(A)] in pore volume between the activated carbon (A) and the activated carbon (B) is from 0.1 mL/g to 1.5 mL/g.

A method of treating a leukemia comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a compound of Formula (I) and/or (II) having the structure: OR2 R R1O n OR2 R R1O n I II wherein: 10 ---- represents a single or a double bond; R is OH when C----R is C—R, and R is O when C----R is C═R; n is 1, 3, 5 or 7; and R1 and R2 are independently hydrogen or acetyl, and/or isomers, stereoisomers or solvates thereof and/or mixtures thereof.

##STR00001##

A process for the synthesis of trans-fused γ-lactones having Formula (IV) from substituted cyclic ketones having Formula (I). A diastereoselective synthesis of (±)-epianastrephin (1) (wherein: R.sup.1 is ethenyl, R.sup.2 and R.sup.3 is methyl, and n is 1), (±)-anastrephin (2) (wherein: R.sup.2 is ethenyl, R.sup.1 and R.sup.3 is methyl and n is 1), and analogs thereof (wherein: R.sup.1 is H, C.sub.1-5 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl, R.sup.2 is H, C.sub.1-5 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl, R.sup.1 and R.sup.2 together with the carbon atom they are attached form a C.sub.3-6 cycloalkyl ring, R.sup.3 is C.sub.1-5 alkyl and n is 0-2):

##STR00001##

A process for the synthesis of trans-fused γ-lactones having Formula (IV) from substituted cyclic ketones having Formula (I). A diastereoselective synthesis of (±)-epianastrephin (1) (wherein: R.sup.1 is ethenyl, R.sup.2 and R.sup.3 is methyl, and n is 1), (±)-anastrephin (2) (wherein: R.sup.2 is ethenyl, R.sup.1 and R.sup.3 is methyl and n is 1), and analogs thereof (wherein: R.sup.1 is H, C.sub.1-5 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl, R.sup.2 is H, C.sub.1-5 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl, R.sup.1 and R.sup.2 together with the carbon atom they are attached form a C.sub.3-6 cycloalkyl ring, R.sup.3 is C.sub.1-5 alkyl and n is 0-2):

##STR00001##

A process for the synthesis of trans-fused γ-lactones having Formula (IV) from substituted cyclic ketones having Formula (I). A diastereoselective synthesis of (±)-epianastrephin (1) (wherein: R.sup.1 is ethenyl, R.sup.2 and R.sup.3 is methyl, and n is 1), (±)-anastrephin (2) (wherein: R.sup.2 is ethenyl, R.sup.1 and R.sup.3 is methyl and n is 1), and analogs thereof (wherein: R.sup.1 is H, C.sub.1-5 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl, R.sup.2 is H, C.sub.1-5 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl, R.sup.1 and R.sup.2 together with the carbon atom they are attached form a C.sub.3-6 cycloalkyl ring, R.sup.3 is C.sub.1-5 alkyl and n is 0-2):

##STR00001##

A continuous flow process for the preparation of one or more esters of lactic acid and 2-hydroxy-3-butenoic acid or α-hydroxy methionine analogues from a sugar in the presence of a solid Lewis acid catalyst and a solvent comprising an organic solvent and water. The invention provides a means for stabilizing a Lewis acid catalyst for use in a continuous reaction process wherein the water is present in an amount of up to or equal to 10 vol. % of the organic solvent.

A continuous flow process for the preparation of one or more esters of lactic acid and 2-hydroxy-3-butenoic acid or α-hydroxy methionine analogues from a sugar in the presence of a solid Lewis acid catalyst and a solvent comprising an organic solvent and water. The invention provides a means for stabilizing a Lewis acid catalyst for use in a continuous reaction process wherein the water is present in an amount of up to or equal to 10 vol. % of the organic solvent.